Patient, donor, and transplant characteristics
| Characteristic . | Value . | Characteristic . | Value . | Characteristic . | Value . |
|---|---|---|---|---|---|
| Age of patients | EBMT risk score | Source of stem cells | |||
| <20 y | 123 (14%) | 1-2 | 56 (6%) | Bone marrow | 139 (15%) |
| 20-40 y | 153 (17%) | 3-4 | 560 (62%) | Peripheral blood stem cells | 769 (85%) |
| 40-60 y | 357 (39%) | 5 | 293 (32%) | Cord blood | 1 (0.1%) |
| 60-70 y | 248 (27%) | Comorbid conditions* | Total body irradiation | ||
| >70 y | 28 (3%) | No | 342 (38%) | No | 628 (69%) |
| Year of treatment | Yes | 382 (42%) | Yes | 279 (31%) | |
| 2008 | 50 (5.5%) | Missing | 185 (20%) | NA | 2 (0.2%) |
| 2009 | 58 (6%) | Karnofsky performance scale index | Conditioning | ||
| 2010 | 51 (6%) | 90-100 | 688 (76%) | Myeloablative | 465 (51%) |
| 2011 | 76 (8.5%) | ≤80 | 214 (23%) | Reduced intensity | 443 (49%) |
| 2012 | 80 (9%) | Missing | 7 (1%) | NA | 1 (0.1%) |
| 2013 | 77 (8%) | No. of allograft | Graft manipulation | ||
| 2014 | 93 (10%) | First | 873 (96%) | None | 191 (21%) |
| 2015 | 100 (11%) | Not first | 36 (4%) | Serotherapy/other | 641 (71%) |
| 2016 | 96 (11%) | Sex matching (D/R) | In vitro T-cell depletion | 77 (8%) | |
| 2017 | 115 (13%) | Male/male | 436 (48%) | HLA-DRB3/4/5 matching | |
| 2018 | 113 (12%) | Female/male | 118 (13%) | Matched | 845 (93%) |
| Type of diagnosis | Male/female | 187 (21%) | 1 mismatch DRB3 | 35 (4%) | |
| Acute leukemia | 506 (56%) | Female/female | 168 (18%) | 1 mismatch DRB4 | 28 (3%) |
| MDS/MPN | 181 (20%) | CMV serostatus matching (D/R) | 1 mismatch DRB3 and DRB4 | 1 (0.1%) | |
| Lymphoid malignancy† | 84 (9%) | Negative/negative | 338 (37%) | Transplant center‡ | |
| NMD | 72 (8%) | Positive/negative | 95 (11%) | 202 | 327 (36%) |
| PCD | 42 (5%) | Negative/positive | 180 (20%) | 208 | 237 (26%) |
| CML | 23 (2%) | Positive/positive | 287 (32%) | 261 | 263 (29%) |
| ST | 1 (0.1%) | Age of donors, y | 334 | 82 (9%) | |
| Status of disease | Median | 31.3 | |||
| Early | 445 (49%) | IQR | 25.2-40.0 | ||
| Intermediate | 279 (31%) | ||||
| Late | 185 (20%) |
| Characteristic . | Value . | Characteristic . | Value . | Characteristic . | Value . |
|---|---|---|---|---|---|
| Age of patients | EBMT risk score | Source of stem cells | |||
| <20 y | 123 (14%) | 1-2 | 56 (6%) | Bone marrow | 139 (15%) |
| 20-40 y | 153 (17%) | 3-4 | 560 (62%) | Peripheral blood stem cells | 769 (85%) |
| 40-60 y | 357 (39%) | 5 | 293 (32%) | Cord blood | 1 (0.1%) |
| 60-70 y | 248 (27%) | Comorbid conditions* | Total body irradiation | ||
| >70 y | 28 (3%) | No | 342 (38%) | No | 628 (69%) |
| Year of treatment | Yes | 382 (42%) | Yes | 279 (31%) | |
| 2008 | 50 (5.5%) | Missing | 185 (20%) | NA | 2 (0.2%) |
| 2009 | 58 (6%) | Karnofsky performance scale index | Conditioning | ||
| 2010 | 51 (6%) | 90-100 | 688 (76%) | Myeloablative | 465 (51%) |
| 2011 | 76 (8.5%) | ≤80 | 214 (23%) | Reduced intensity | 443 (49%) |
| 2012 | 80 (9%) | Missing | 7 (1%) | NA | 1 (0.1%) |
| 2013 | 77 (8%) | No. of allograft | Graft manipulation | ||
| 2014 | 93 (10%) | First | 873 (96%) | None | 191 (21%) |
| 2015 | 100 (11%) | Not first | 36 (4%) | Serotherapy/other | 641 (71%) |
| 2016 | 96 (11%) | Sex matching (D/R) | In vitro T-cell depletion | 77 (8%) | |
| 2017 | 115 (13%) | Male/male | 436 (48%) | HLA-DRB3/4/5 matching | |
| 2018 | 113 (12%) | Female/male | 118 (13%) | Matched | 845 (93%) |
| Type of diagnosis | Male/female | 187 (21%) | 1 mismatch DRB3 | 35 (4%) | |
| Acute leukemia | 506 (56%) | Female/female | 168 (18%) | 1 mismatch DRB4 | 28 (3%) |
| MDS/MPN | 181 (20%) | CMV serostatus matching (D/R) | 1 mismatch DRB3 and DRB4 | 1 (0.1%) | |
| Lymphoid malignancy† | 84 (9%) | Negative/negative | 338 (37%) | Transplant center‡ | |
| NMD | 72 (8%) | Positive/negative | 95 (11%) | 202 | 327 (36%) |
| PCD | 42 (5%) | Negative/positive | 180 (20%) | 208 | 237 (26%) |
| CML | 23 (2%) | Positive/positive | 287 (32%) | 261 | 263 (29%) |
| ST | 1 (0.1%) | Age of donors, y | 334 | 82 (9%) | |
| Status of disease | Median | 31.3 | |||
| Early | 445 (49%) | IQR | 25.2-40.0 | ||
| Intermediate | 279 (31%) | ||||
| Late | 185 (20%) |
CML, chronic myeloid leukemia; CMV, cytomegalovirus; D, donor; IQR, interquartile range; MDS/MPN, myelodysplastic/myeloproliferative syndromes; NA, nonavailable; NMD, all nonmalignant disorders; PCD, plasma cell disorders; R, recipient; ST, solid tumor.
Based on the hematopoietic cell transplantation–specific comorbidity index.
Lymphoid malignancy regroups non-Hodgkin lymphoma, Hodgkin disease, and chronic lymphatic leukemia/prolymphocytic leukemia.
The transplant center code according to European Society for Blood and Marrow Transplantation (EBMT) is listed for the 4 allogeneic centers of Switzerland. All covariables tested in univariate analyses are shown here.